Hundreds of pharmaceutical sales reps join lawsuit demanding overtime pay and class action status
Hundreds of Pfizer pharmaceutical sales reps in New York have joined a class action lawsuit demanding overtime pay and seeking class action status in New York, California and Illinois. Many of the employees were laid off following Pfizer's merger with Wyeth in 2009, which led to 20,000 layoffs. By the first few months of this year, hundreds of pharmaceutical sales reps have joined the case.
Pfizer is the biggest drug company in the U.S. and has the biggest workforce of any pharmaceutical company, employing around 110,000 employees. Around 8,000 of those employees are sales representatives. Except in certain areas, the Supreme Court has let stand rulings that require drug companies to pay overtime to sales reps who work over 40 hours a week.
Many sales reps are instructed not to record their hours for work duties performed off the clock, including:
Pharmaceutical companies that may have to pay backpay:
Pending overtime cases:
Article: Pharmaceutical Sales representative - Read how the FLSA affects your paycheck
FAQ: Am I exempt from overtime as a pharmaceutical sales representative?
If you are denied your correct pay or your employer refuses to pay you overtime, you probably have questions. Send us a confidential contact form or order our free wage and overtime guide to tell us about your case. Our firm is in Houston, Texas, but we maintain a national practice.
The Texas overtime lawyers at Kennedy Hodges represent workers nationwide and across Texas in:
Houston, Dallas, Austin, San Antonio, Fort Worth, Pasadena, Laredo, Sugar Land, Lubbock, Illinios, New York, Massachusetts, Los Angeles, Chicago, Philadelphia, Phoenix, San Diego, San Jose, Jacksonville, Indianapolis, San Francisco, Columbus, Charlotte, Detroit, and more.
Post a Comment to "Pfizer pharmaceutical sales reps join lawsuit demanding overtime pay (New York, Illinois)"
To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."